X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The collaboration aims to research on PST2744 (istaroxime), a SERCA2a activator, an important target for the Company’s cardiovascular portfolio, including heart failure.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chang Gung University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2024
Details:
Under the agreement, Lee will be responsible for the development and commercialization of Windtree’s product candidate PST2744 (istaroxime), a first-in-class dual-mechanism therapy, in Greater China, including for acute heart failure and cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lee’s Pharmaceutical
Deal Size: $138.1 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 17, 2024
Details:
PST2744 (Istaroxime) is a Na/K ATPase 2 inhibitor & a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. It is under phase 2 clinical development for the treatment of cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
PST2744 (istaroxime) is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure. It is under phase 2 clinical development for the treatment of Early Cardiogenic Shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The Company intends to use the net proceeds of the offering to extend enrollment and complete a Phase 2 clinical trial for PST2744 (istaroxime), a potent inhibitor of Na+,K+-ATPase, in cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co. Inc.
Deal Size: $12.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 24, 2023
Details:
The Company will use the proceeds to extend enrollment and complete a Phase 2 clinical trial for PST2744 (istaroxime), a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase), in cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co. Inc.
Deal Size: $10.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 20, 2023
Details:
PST2744 (istaroxime) is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism of the SERCA2a calcium pump activation on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
PST2744 (istaroxime) is a positive inotropic agent that increases myocardial contractility by inhibiting of Na+/K+- ATPase, it also facilitates myocardial relaxation via SERCA2a calcium pump activation on sarcoplasmic reticulum enhancing cytoplasmic calcium reuptake.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
PST2744 (istaroxime) is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism of the SERCA2a calcium pump activation on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2023
Details:
Istaroxime (PST2744) is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Patients treated with PST2744 (Istaroxime) experienced a substantial increase in stroke volume that contributed to an increased cardiac output without increasing heart rate. The study met several other secondary endpoint assessments of cardiac function.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
PST2744 (Istaroxime) is a first-in-class dual mechanism positive inotropic agent therapy designed to improve both systolic and diastolic cardiac function.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the PST2744 (istaroxime) group performing significantly better than the control group Increased SBP also persisted through 24 hours.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2022
Details:
The study met its primary endpoint in SBP profile over six hours, with PST2744 (istaroxime) treated group performing significantly better compared to the control group, and significantly improved the systolic blood pressure profile.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Istaroxime, a positive inotropic agent increases myocardial contractility through inhibition of Na+/K+- ATPase with a complementary mechanism that facilitates myocardial relaxation enhancing calcium reuptake from the cytoplasm.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2022
Details:
Data from multiple Phase 2 studies in patients with acute heart failure (AHF) demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without causing heart rate increases or rhythm disturbances.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
Based on clinical result, istaroxime has potential to deliver effects of improving cardiac function in decompensated heart failure without the deleterious effects of decreasing blood pressure, increasing heart rate, myocardial damage, or increased risk of arrhythmias.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
Windtree intends to use the net proceeds from the offering for the continued advancement of its lead product candidate istaroxime developed to improve cardiac function in patients with acute heart failure as well as in early cardiogenic shock.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oppenheimer & Co.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 25, 2021
Details:
The istaroxime Phase 2 study is an international randomized double blind placebo controlled study to assess the effect of istaroxime in patients with early cardiogenic shock due to heart failure.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PST2744
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2020
Details:
Efficacy of 24 Hour Istaroxime Infusion is Similar Between Caucasian and Asian Patients Hospitalized for Acute Heart Failure.
Lead Product(s): Istaroxime
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
